Pioneering Generative AI
for Peptide Drug Design

Validated across the preclinical discovery pipeline, MAUD 1.0 designs peptide macrocycles from scratch — de novo— for complex drug targets, including challenging Protein-Protein Interfaces.

Trusted by top-10 pharma partners and backed by leading VCs, our platform has demonstrated:

nM-level Potency

Oral bioavailability

Cell-permeability

>90% hit rate

‍‍Unlike traditional screening, MAUD 1.0 combines generative AI with physics-based models and quantum simulations to design and optimize drug-like peptides—accelerating discovery and expanding the accessible chemical space.

See MAUD 1.0 in Action